On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 ...

Pfizer wins a $10 billion deal for weight-loss drugmaker Metsera, ending its bidding war with Danish rival Novo Nordisk.

The months-long bidding war for obesity drugmaker Metsera came to an end late Friday, but not before federal regulators ...

COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion ...

Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

With U.S. stock markets set to open in two hours, Maplebear Inc. (CART) was up 8.1% in pre-market trading, and Caris Life Sciences Inc. (CAI) was up 7.3%.

Metsera said it has struck a revised merger agreement with Pfizer that values the company at up to $86.25 per share in cash.

The contract chip maker's sales rose last month at the slowest pace since February 2024, but [remained in double-digits]( ...

Pharmaceutical giant Pfizer has finally acquired development-stage obesity drugmaker Metsera Inc., in an intense bidding war against the Danish drugmaker Novo Nordisk for over $10 billion.

Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.